Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simplified staging for hepatocellular carcinoma.

Jean-Nicolas Vauthey1, Gregory Y Lauwers, Nestor F Esnaola

  • 1International Cooperative Study Group on Hepatocellular Carcinoma, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA. jvauthey@mdanderson.org

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 16, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pilot Study of Plasma Cell-Free DNA Fragmentomics in Gallbladder Cancer.

JHEP reports : innovation in hepatology·2026
Same author

ctxR: Utilities for interacting with the CTX APIs.

NAM journal·2026
Same author

Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.

Cancer cytopathology·2026
Same author

Growth Hormone Pathway as a Prognostic and Therapeutic Biomarker in Patients With Unresectable Hepatocellular Carcinoma Treated With Radiation Therapy.

Advances in radiation oncology·2026
Same author

Generation of CCR4/CD7 Bispecific CAR-T Cells Resistant to Fratricide and Exhaustion.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma.

Journal of hepatocellular carcinoma·2025

The current American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) is complex and inaccurate. A new, simplified HCC staging system based on vascular invasion, tumor number, and size is proposed for better patient stratification.

Area of Science:

  • Hepatobiliary surgery
  • Surgical oncology
  • Gastroenterology

Background:

  • The American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) requires improvement for accurate patient prognostication.
  • Current staging lacks precision in stratifying survival outcomes for HCC patients undergoing resection.

Purpose of the Study:

  • To evaluate the efficacy of the current AJCC tumor (T) categories in stratifying survival for 557 HCC patients post-resection.
  • To develop a simplified and more accurate staging system for HCC based on independent predictors of survival.

Main Methods:

  • Analysis of survival data from 557 patients who underwent complete HCC resection across four institutions.
  • Identification of independent predictors of survival, including vascular invasion, tumor number, tumor size, and liver fibrosis.

Related Experiment Videos

  • Development of a novel, simplified HCC staging system incorporating these predictors.

    • Main Results:

    • The current AJCC T classification showed similar survival for T1/T2 and T3/T4 patients, indicating poor stratification.
    • Key predictors of mortality included major vascular invasion, microvascular invasion, severe fibrosis/cirrhosis, multiple tumors, and tumor size >5 cm.
    • A simplified three-tiered staging system was proposed, significantly improving prognostic stratification (P <.001).

    Conclusions:

    • The existing AJCC staging system for HCC is overly complex and inadequately stratifies patient prognosis.
    • A simplified HCC staging model integrating vascular invasion, tumor number, tumor size, and fibrosis offers improved accuracy.
    • This new model promises more precise risk stratification for patients with resectable HCC.